Wave Life Sciences CEO to Present at Cantor Healthcare Conference
Event summary
- Wave Life Sciences CEO Paul Bolno to participate in analyst-led fireside chat on September 10, 2026.
- Live webcast available via Wave’s Investor Relations page.
- Company focuses on RNA medicines for rare and common disorders.
- Key programs include obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008).
- Additional clinical programs in Duchenne muscular dystrophy and Huntington’s disease.
The big picture
Wave Life Sciences is positioning itself as a leader in RNA medicines, leveraging its PRISM platform to address both rare and common disorders. The company’s participation in the Cantor 2026 Global Healthcare Conference underscores its strategic focus on obesity, liver disease, and neurological conditions, areas with significant unmet medical needs. The presentation provides an opportunity to gauge investor interest in Wave’s pipeline and its ability to compete with larger biotech players in the RNA therapeutics market.
What we're watching
- Pipeline Progress
- How Wave’s obesity and liver disease programs advance following this presentation.
- Investor Sentiment
- Whether the conference presentation shifts market perception of Wave’s RNA medicines platform.
- Competitive Positioning
- The pace at which Wave can differentiate itself in the crowded RNA therapeutics space.
Related topics